AstraZeneca's Tagrisso with chemo significantly improves survival and progression-free outcomes in EGFR-mutant NSCLC, final trial data shows.

Pfizer and Novo Nordisk have underperformed the market over the past year. Pharmaceutical giants Pfizer (NYSE: PFE) and Novo ...

Johnson & Johnson JNJ, on its second-quarter conference call, stated that it expects its oncology sales to reach $50 billion ...

Conversations with the Trump administration on its “most favored nation” policy have been productive, the executive said ...

Johnson & Johnson shows steady growth in Q2, driven by medtech and oncology, yet talc litigation overshadows. Click for my ...

ABBV's oncology sales might have dipped in Q2 as gains from newer drugs face pressure from Imbruvica's ongoing decline.

Pfizer’s trading volume surged to $13.51 billion, more than doubling from the prior day. Despite the impressive spike in ...

Analysts expect Johnson & Johnson to report an earnings per share (EPS) of $2.67. Johnson & Johnson bulls will hope to hear ...

PFE's oncology unit is in focus ahead of Q2 results, with key drugs facing both rising demand and market pressure.

Amgen combines patent protection, a robust pipeline, and strong execution for defensive investment. Click here to read an ...